Breast Cancer: Diagnosis and Staging

Breast Cancer: Diagnosis and Staging

Breast Cancer: Diagnosis and Staging

On this page

Breast Cancer: Risks & Alerts - Spotting Trouble Early

  • Major Risk Factors:
    • Non-Modifiable:
      • Age (↑ risk >50 yrs), Female sex
      • Family Hx (1st degree), BRCA1/BRCA2 mutations
      • Personal Hx of breast Ca, LCIS, ADH
      • Early menarche (<12 yrs), Late menopause (>55 yrs)
      • Dense breast tissue
    • Modifiable:
      • Nulliparity or late first child (>30 yrs)
      • No breastfeeding
      • Combined HRT, OCPs (slight risk)
      • Obesity (postmenopausal), Alcohol, Radiation exposure
  • Clinical Alerts (Symptoms):
    • Painless lump (most common presentation)
    • Nipple changes: inversion/retraction, spontaneous bloody/serous discharge, Paget’s disease (eczematous changes)
    • Skin changes: dimpling (peau d’orange), tethering, erythema, ulceration
    • Axillary or supraclavicular lymphadenopathy
    • Breast asymmetry, contour changes, persistent pain (less common) Breast Cancer: Risk Factors, Progression, Treatment

⭐ Most common site of breast cancer: Upper Outer Quadrant (UOQ).

Breast Cancer: Detective Work - Confirming Suspicions

  • Screening Methods:
    • Mammography: Annually for women aged >40-45 years (guidelines vary).
    • Clinical Breast Exam (CBE): Part of routine check-ups.
    • Breast Self-Exam (BSE): Promotes awareness.
  • Diagnostic Pathway:

    ⭐ Triple Assessment (Clinical exam, Imaging, Pathology/Biopsy) is key for diagnosis of palpable breast lumps.

*   **Imaging Insights**:
    *   Mammography: Detects masses, architectural distortion, microcalcifications. BI-RADS score guides management.
    *   Ultrasound: Differentiates solid vs. cystic lesions; primary tool <**35** yrs; guides biopsy.
    *   MRI: High-risk screening; assesses extent, multifocality, response to neoadjuvant chemotherapy.
*   **Pathology Confirmation**:
    *   Core Needle Biopsy (CNB): **Gold standard** for diagnosis. Provides tissue for histology, grade, and receptor status (ER, PR, HER2).
    *   FNAC: Limited; cannot assess invasiveness.
  • Staging: Based on TNM classification (Tumor size, Nodal status, Metastasis).

Breast Cancer: Lab Deep Dive - Types & Traits

  • Histopathology (Biopsy):
    • Invasive Ductal Carcinoma (IDC) NOS: Most common (~75%). Gritty, stellate appearance.
    • Invasive Lobular Carcinoma (ILC): ~10-15%. "Indian file" pattern (single cells in rows), often multifocal/bilateral.
    • Others: Tubular, Mucinous (Colloid), Medullary, Papillary.
  • Key Receptors & Markers (IHC Panel):
    • Estrogen Receptor (ER)
    • Progesterone Receptor (PR)
    • HER2/neu (Human Epidermal growth factor Receptor 2)
    • Ki-67 (Proliferation index)
  • Molecular Subtypes (Prognostic & Predictive):
    • Luminal A: ER+/PR+, HER2-, Low Ki-67. Best prognosis.
    • Luminal B: ER+/PR+, HER2+ OR (HER2- & High Ki-67).
    • HER2 Enriched: ER-/PR-, HER2+.
    • Basal-like (TNBC): ER-/PR-, HER2-. Breast Cancer Subtypes and Prognosis

⭐ Triple-negative breast cancer (TNBC) - ER negative, PR negative, HER2 negative - generally has the poorest prognosis among common subtypes.

Breast Cancer: Staging Showdown - Sizing Up the Foe

  • TNM System (AJCC 8th Ed.): Key for prognosis & therapy.
    • T (Tumor Size):
      • Tis: In situ
      • T1: ≤ 2 cm (T1mi ≤ 0.1 cm; T1a >0.1-0.5 cm; T1b >0.5-1 cm; T1c >1-2 cm)
      • T2: > 2 cm - ≤ 5 cm
      • T3: > 5 cm
      • T4: Chest wall/skin invasion; inflammatory (T4d)
    • N (Nodes):
      • N0: No regional LN
      • N1: Mobile ipsilateral axillary
      • N2: Fixed axillary OR isolated internal mammary (clinically apparent)
      • N3: Infraclavicular/supraclavicular/internal mammary + axillary
    • M (Metastasis):
      • M0: No distant
      • M1: Distant
  • Staging Types: Clinical (cTNM), Pathological (pTNM).

⭐ Axillary lymph node status is the single most important prognostic factor in early-stage, operable breast cancer. Breast cancer biomarkers and treatment by stage

High‑Yield Points - ⚡ Biggest Takeaways

  • Triple assessment (clinical exam, imaging, pathology) is vital for diagnosis.
  • Mammography is key for screening (>40 yrs); USG for younger or dense breasts.
  • MRI aids high-risk screening, staging, and assessing NACT response.
  • Core needle biopsy is the gold standard for definitive histological diagnosis.
  • Staging uses the TNM system; pathological staging is most accurate.
  • ER, PR, and HER2/neu status are crucial for prognosis and guiding therapy.
  • Axillary lymph node status remains the single most important prognostic factor.

Practice Questions: Breast Cancer: Diagnosis and Staging

Test your understanding with these related questions

Fluorescence in situ hybridization (FISH) is required in which of the following interpretations of Her2/neu?

1 of 5

Flashcards: Breast Cancer: Diagnosis and Staging

1/10

According to the T category under AJCC classification of breast cancer, tumor size _____ mm is T3

TAP TO REVEAL ANSWER

According to the T category under AJCC classification of breast cancer, tumor size _____ mm is T3

>50

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial